Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.45−0.29 (-1.40%)
Close on Nov 17, 2026Market cap $23.49BP/E –Yield 2.35%
Viatris total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Viatris's total debt was $13.35B at Jun 30, 2026. For fiscal 2025 it was $14.41B, up 2.6% from the year before. The highest annual figure on record is $24.69B in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.41B | +2.6% |
| FY2024 | Dec 31, 2024 | $14.04B | -22.5% |
| FY2023 | Dec 31, 2023 | $18.12B | -5.9% |
| FY2022 | Dec 31, 2022 | $19.27B | -10.7% |
| FY2021 | Dec 31, 2021 | $21.58B | -12.6% |
| FY2020 | Dec 31, 2020 | $24.69B | +94.8% |
| FY2019 | Dec 31, 2019 | $12.67B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.35B | -7.7% |
| Q1 FY2026 | Mar 31, 2026 | $14.34B | +1.1% |
| Q4 FY2025 | Dec 31, 2025 | $14.41B | +2.6% |
| Q3 FY2025 | Sep 30, 2025 | $14.43B | -8.3% |
| Q2 FY2025 | Jun 30, 2025 | $14.46B | -15.4% |
| Q1 FY2025 | Mar 31, 2025 | $14.18B | -21.1% |
| Q4 FY2024 | Dec 31, 2024 | $14.04B | -22.5% |
| Q3 FY2024 | Sep 30, 2024 | $15.74B | -14.3% |
| Q2 FY2024 | Jun 30, 2024 | $17.09B | -8.0% |
| Q1 FY2024 | Mar 31, 2024 | $17.96B | -3.3% |
| Q4 FY2023 | Dec 31, 2023 | $18.12B | -5.9% |
| Q3 FY2023 | Sep 30, 2023 | $18.38B | -5.7% |
| Q2 FY2023 | Jun 30, 2023 | $18.57B | -7.0% |
| Q1 FY2023 | Mar 31, 2023 | $18.57B | -13.1% |
| Q4 FY2022 | Dec 31, 2022 | $19.27B | -10.7% |
| Q3 FY2022 | Sep 30, 2022 | $19.48B | -10.4% |
| Q2 FY2022 | Jun 30, 2022 | $19.97B | -13.4% |
| Q1 FY2022 | Mar 31, 2022 | $21.36B | -12.3% |
| Q4 FY2021 | Dec 31, 2021 | $21.58B | -12.6% |
| Q3 FY2021 | Sep 30, 2021 | $21.74B | +88.4% |
| Q2 FY2021 | Jun 30, 2021 | $23.07B | +102.6% |
| Q1 FY2021 | Mar 31, 2021 | $24.36B | +92.2% |
| Q4 FY2020 | Dec 31, 2020 | $24.69B | – |
| Q3 FY2020 | Sep 30, 2020 | $11.54B | – |
| Q2 FY2020 | Jun 30, 2020 | $11.39B | – |
| Q4 FY2019 | Dec 31, 2019 | $12.67B | – |
See a number that looks wrong?